McKesson Corporation (MCK)

Over the past six months, McKesson's stock has experienced fluctuations. Key events include strong Q3 fiscal 2026 earnings driven by North American demand, which led to raised FY2026 guidance. McKesson announced its intent to spin off its Medical-Surgical Solutions segment and completed the sale of its distribution business in Norway. The company also secured a $5 billion credit line maturing in 2031.

McKesson's Medical-Surgical Solutions segment experiences demand seasonality, being highly dependent on seasonal illnesses. The company uses data and machine learning to forecast demand fluctuations and manage inventory. Recent trends show strong demand in North America for prescription transaction volumes, specialized drugs, and oncological drugs, as well as a surge in demand for GLP-1 weight-loss medications and a rebound in primary care visits.

McKesson Corporation is a major healthcare supply chain management company in North America. It distributes pharmaceuticals, provides health information technology, medical supplies, and health management tools. Its business segments include U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

McKesson's market presence is mainly in North America, generating approximately 92% of its fiscal 2024 revenue from this region. It has a dominant position in the U.S. and significant operations in Canada. Outside North America, McKesson has a smaller presence in Europe, focusing on specialty pharmaceutical distribution and oncology services. The company's headquarters are in Irving, Texas, and it operates numerous distribution centers, pharmacy locations, and business offices in the U.S. and internationally.

In the past year, McKesson has focused on advancing health outcomes, improving healthcare access and equity, diversifying clinical trials, and embracing technology and innovation. It has also engaged in sustainability initiatives and community impact days. However, McKesson has faced reputational challenges, including being named in a federal lawsuit for allegedly profiting from the opioid epidemic.

McKesson's ownership is primarily dominated by institutional investors, who collectively own approximately 83% to 88% of the common stock. Major institutional owners include The Vanguard Group, BlackRock Institutional Trust Company, and State Street Investment Management. Hedge funds like Balyasny Asset Management and Glenview Capital Management have also increased their stakes.